Radar Therapeutics develops precision-expressed mRNA-based therapeutics that utilize programmable RNA sensors to read cellular profiles and deliver targeted genetic payloads. This technology enables the reprogramming of specific cells at the right time, minimizing off-target effects and enhancing the efficacy of treatments for complex diseases.
Funding
$13.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NBFounders
Product
Problem
Current mRNA-based therapeutics lack the ability to differentiate between cell types, leading to potential off-target effects and reduced efficacy in treating complex diseases. Existing mRNA technologies can write functions into cells but cannot read the cell's profile to ensure targeted delivery and action.
Solution
Radar Therapeutics is developing precision-expressed mRNA-based therapeutics that utilize programmable RNA sensors to read cellular profiles and deliver targeted genetic payloads only to desired cells at the right time. The RADAR platform leverages single-cell transcriptomic data and RNA-editing enzymes to create "smart" mRNAs that can read a cell's information in real time. This approach enables precise targeting and reprogramming of specific cells, minimizing off-target effects and enhancing treatment efficacy. The platform offers safe and scalable in vivo reprogramming, eliminating the costs and risks associated with ex vivo treatments.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing targeted therapies for complex diseases, particularly those requiring precise control over gene expression in specific cell types.
Features
- Programmable RNA sensors that read cellular RNA profiles for targeted delivery
- Precision mRNA control for targeted, timely, and controlled reading of the mRNA message
- Ability to reprogram only desired cells within the body with high accuracy
- Utilizes single-cell transcriptomic data to identify targetable cell signatures
- Employs RNA-editing enzymes and logic gates to create "smart" mRNAs
- Enables in vivo reprogramming, reducing costs and risks of ex vivo treatments
- Designed for safe and scalable therapeutic development